Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722162 · ClinicalTrials.gov registry record · Phase 2
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01722162 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 47 participants.
The verdict
NCT01722162, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how giving a drug called levocetirizine to patients with colorectal cancer affects their tumor response to capecitabine and bevacizumab. Capecitabine is a chemotherapy drug that blocks tumor growth by disrupting DNA and RNA synthesis and repair (cell division and survival). Bevacizumab is a monoclonal antibody that blocks the ability of tumors to grow and spread by inhibiting the growth of blood vessels that feed them. Patients with colorectal cancer can develop a resistance to the effects of bevacizumab. Levocetirizine may decrease tumor resistance to bevacizumab. Giving bevacizumab, capecitabine, and levocetirizine dihydrochloride together may be an effective treatment for refractory colorectal cancer.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Levocetirizine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722162
The ClinicalTrials.gov registry entry for NCT01722162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01722162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01722162 about?
NCT01722162 is a clinical study titled "Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer". This randomized phase II trial studies how giving a drug called levocetirizine to patients with colorectal cancer affects their tumor response to capecitabine and bevacizumab. Capecitabine is a chemotherapy drug that blocks tumor growth by disrupting DNA and RNA synthesis and repair (cell division a...
What is the current status of trial NCT01722162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01722162?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Levocetirizine (DRUG).
Who is sponsoring clinical trial NCT01722162?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.